Table 3

Incidence of the primary and secondary efficacy outcomes stratified by trial group

OutcomeTotal
n=131
Intervention
n=66
Control
n=65
OR (95% CI),p value
Early discharge within 4 hour without prevalent AMI or incident
MACE at 30 days, n (% (95% CI))
22 (17%)17 (26%)5 (8%)Unadjusted
Adjusted*
4.16 (1.43 to 12.09), p0.009
5.45 (1.73 to 17.11), p=0.004
Prevalent AMI, n (%)9 (7)3 (5)6 (9)0.47 (0.11 to 1.96), p=0.30
Incident MACE at 30 days†, n (%)6 (5)3 (5)3 (5)0.98 (0.19 to 5.06), p=0.985
Incident MACE at 90 days†, n (%)9 (7)5 (8)4 (6)1.36 (0.35 to 5.34), p=0.656
Incident MACE at 180 days†, n (%)11 (8)6 (9)5 (8)1.30 (0.37 to4.56), p=0.678
Hospital length of stay (median, IQR)1 (0–1)1 (0–1)1 (0–1)p=0.54‡
Patient satisfaction (mean score, SD)3.8 (1.0)3.8 (1.0)3.8 (1.1)p=0.80‡
Re-attendance at an ED, n (%)18 (23)10 (23)8 (23)p=0.97
Any further investigation for heart disease within 30 days, n (%)27 (21)15 (23)12 (18)p=0.55
Myocardial perfusion imaging (thallium scan) within 30 days, n (%)8 (28)3 (19)5 (38)p=0.24
Stress ECG within 30 days, n (%)1 (4)1 (7)0 (0)p=0.34
Coronary angiography within 30 days, n (%)9 (32)4 (27)5 (38)p=0.51
  • *Adjusted for trial centre, age, gender, cardiovascular risk factors and history of prior coronary artery disease. This is the prespecified primary analysis.

  • †Incident death, AMI or coronary revascularisation (not including prevalent AMI). NB, no patients who were discharged early developed a MACE.

  • Mann-Whitney U test.

  • MACE, major adverse cardiac event.